Gilead Sciences, Inc.
NEWS
At Kite, Shaw will focus on turning around the company’s flagship CAR-T treatment Yescarta, as well as focus on the development of other cancer-targeting cell therapies.
Under the terms of the collaboration and license deal, Gilead will fund Renown IHI’s efforts to sequence and analyze the DNA of 15,000 people who have been diagnosed with NASH or nonalcoholic fatty liver disease in addition to a control group of 40,000 people in Nevada.
Gilead is paying Lyndra $15 million upfront to develop a formulation for HIV that can be taken once a week, as opposed to every day.
Based on positive data from its FINCH program, Gilead aims to seek regulatory approval for its Jak inhibitor.
The focus will be on discovering drugs that use the body’s natural protein control processes.
AbCellera will use its technology to look for ultra-rare antibodies with specific properties defined by Gilead.
At the American Society of Clinical Oncology meeting in Chicago, Kite presented updated safety data from the ZUMA-1 trial that introduced a regimen of steroids to CAR-T patients who show early signs of neurologic events reduces the safety concerns associated the CAR-T treatment.
Biocartis Group NV, an innovative molecular diagnostics company, announced that it has entered into a Master Development and Commercialization Agreement with Kite, a Gilead Company.
Gilead’s Truvada is expected to lose patent protection in 2021, but a recent court decision in Europe could change that.
JOBS
IN THE PRESS